Table 4 Ongoing clinical trials with epigenetic drugs in CM patients
From: Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies
| Â | Molecule (commercial name) | Tumor | Phase | Combination | Identifiera |
|---|---|---|---|---|---|
inhibitors of DNMT | 5-azacytidine (Vidaza) | Melanoma (Skin) | I | Recombinant Interferon α-2b | NCT00398450 |
|  |  | Kidney Cancer, Melanoma (Skin) | I | Recombinant Interferon α-2b | NCT00217542 |
|  | 5-Aza-2'-deoxycytidine (Dacogen, Decitabine) | Melanoma | I, II | Pegylated Interferon α-2b | NCT00791271 |
| Â | Â | Metastatic Melanoma | I, II | Temozolomide, Panobinostat | NCT00925132 |
|  |  | Melanoma | I, II | Pegylated Interferon α-2b | NCT00791271 |
| Â | Â | Melanoma | I, II | Temozolomide | NCT00715793 |
inhibitors of HDAC | Valproic acid (Depakote, Depakote ER, Depakene, Depacon, Stavzor) | Melanoma | I, II | Karenitecin | NCT00358319 |
| Â | FR901228 (Romidepsin) | Intraocular Melanoma, Unresectable stage III or stage IV Melanoma | II | Â | NCT00104884 |
| Â | MS-275 (Entinostat, SNDX-275, BAY86-5274) | Melanoma | II | Â | NCT00185302 |
| Â | Suberoylanilide hydroxamic acid, SAHA (Vorinostat, Zolinza) | NSCLC, Pancreatic Cancer, Melanoma, Lymphoma | I | Protesome inhibitor NPI-0052 | NCT00667082 |
| Â | Â | Intraocular Melanoma, Metastatic or Unresectable Melanoma | II | Â | NCT00121225 |